GLP-1 Market
LLY $1115.70 ▼ -0.7% NVO $43.07 ▼ -2.1% PFE $27.72 ▲ +0.3% VKTX $31.98 ▼ -0.5% KLRA $13.94 ▼ -6.5% GPCR $38.66 ▼ -2.3% RHHBY $52.82 ▼ -0.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Veverimer

Company
Renibus Therapeutics, Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 12, 2026

Find a Clinical Trial Near Me

See recruiting studies for Veverimer and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07355062

    A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis

    Not yet reported Renibus Therapeutics, Inc. 150 participants Est. completion 2027-06 24 sites Stand-alone
    Chronic kidney disease Other conditions: Metabolic Acidosis
    View official trial listing →
  • Recruiting NCT NCT07473713

    Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia

    Not yet reported Tufts Medical Center 60 participants Est. completion 2028-05-01 1 site Stand-alone
    Other conditions: Osteopenia
    View official trial listing →
  • Completed NCT NCT02809183

    Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis

    Not yet reported, Not yet reported Tricida, Inc. 135 participants Est. completion 2016-11 5 sites
    Other conditions: Acidosis
    View official trial listing →
  • Completed NCT NCT03317444

    Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease

    Not yet reported Tricida, Inc. 217 participants Est. completion 2018-05-15 44 sites
    Other conditions: Metabolic Acidosis
    View official trial listing →
  • Completed NCT NCT03390842

    Long-term Safety Extension to Study TRCA-301

    Not yet reported Tricida, Inc. 196 participants Est. completion 2019-02-22 29 sites
    Other conditions: Metabolic Acidosis
    View official trial listing →
  • Terminated NCT NCT03710291

    Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis

    Not yet reported Tricida, Inc. 1480 participants Est. completion 2022-09-27 203 sites
    Chronic kidney disease Other conditions: Metabolic Acidosis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.